| Verified Reactivity | Mouse |
|---|---|
| Antibody Type | Monoclonal |
| Host Species | Rat |
| Immunogen | Mouse thymus or spleen |
| Formulation | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide. |
| Preparation | The antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions. |
| Concentration | 0.5 mg/ml |
| Storage & Handling | The antibody solution should be stored undiluted between 2°C and 8°C. Do not freeze. |
| Application | FC - Quality tested |
| Recommended Usage | Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. |
| Application Notes | Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45. Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164). |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Application References(PubMed link indicates BioLegend citation) | Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC) Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP) Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC) Seaman WE. 1983. J. Immunol. 130:1713. (CMCD) Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC) Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed Liu F, et al. 2012. Blood. 119:3295. PubMed Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed |
|---|
| Product Citations | Yen W, et al. 2012. Clin Cancer Res. 18:5374. PubMed Dell'Aringa M, et al. 2018. Mucosal Immunol. 1.207638889. PubMed Shiroshita K, et al. 2022. Cell Rep Methods. 2:100354. PubMed Matsuzawa M, et al. 2023. Nat Commun. 14:1417. PubMed Papadopoulou D, et al. 2023. JCI Insight. 8:. PubMed Lv X, et al. 2023. Acta Pharm Sin B. 13:1631. PubMed Fadzeyeva E, et al. 2023. iScience. 26:106748. PubMed Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed Tang Y, et al. 2022. Dev Cell. 57:480. PubMed Gbyli R, et al. 2022. Leukemia. 36:1313. PubMed Tarban N, et al. 2022. Cells. 11:. PubMed Fujimori S, et al. 2022. Elife. 11:. PubMed Lv X, et al. 2022. Acta Pharm Sin B. 12:735. PubMed Kaminitz A, et al. 2013. Int Immunol. 25:485. PubMed Larsen SB, et al. 2021. Cell Stem Cell. 28:1758. PubMed Chiang HC, et al. 2018. Sci Rep. 8:2731. PubMed Xie T, et al. 2021. Sci Adv. 7: . PubMed Muhsin-Sharafaldine M, et al. 2017. Biochem Biophys Res Commun. 10.1016/j.bbrc.2017.03.138. PubMed Wagner F, et al. 2016. J Bone Joint Surg Am. 98: 916 - 925. PubMed Nair S, et al. 2016. Nat Commun. 7:10913. PubMed Fu R, et al. 2019. Nat Commun. 10:3210. PubMed Leimkühler NB, et al. 2020. Cell Stem Cell. 28:637. PubMed Kurane T, et al. 2020. Okajimas Folia Anat Jpn. 96:49:00. PubMed Ibrahim AM, et al. 2021. Breast Cancer Res. 23:90. PubMed Karaman S, et al. 2022. J Exp Med. 219:. PubMed Sitaraman S, et al. 2021. JCI Insight. 6:. PubMed Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed Howard E, et al. 2020. J Allergy Clin Immunol. . PubMed Wang Y, et al. 2021. Sci Rep. 1.429861111. PubMed Nevius E, et al. 2015. J Exp Med. 212: 1931 - 1946. PubMed Hartwig T et al. 2018. Cell reports. 25(13):3564-3572 . PubMed Wang Z, et al. 2022. Cell Mol Immunol. 19:210. PubMed Shen Z, et al. 2021. iScience. 24:103014. PubMed Lv J, et al. 2021. Cell Discov. 7:24. PubMed Chatterjee S, et al. 2014. PLoS One. 9:87858. PubMed Ludwik KA, et al. 2021. STAR Protocols. 2(1):100270. PubMed Derecka M, et al. 2020. Nat Immunol. 261:21. PubMed Adam RC et al. 2018. Cell stem cell. 22(3):398-413 . PubMed Watson JK, et al. 2020. Sci Rep. 10:10490. PubMed Zhu H, et al. 2020. J Bone Miner Res. 35:698. PubMed Lin C, et al. 2022. Nat Commun. 13:6869. PubMed Deerhake ME, et al. 2021. Immunity. 54(3):484-498.e8. PubMed Sitaraman S, et al. 2019. Sci Rep. 9:12509. PubMed Lüönd F, et al. 2022. STAR Protoc. 3:101438. PubMed Pilling D, Gomer R 2014. PLoS One. 9:93730. PubMed Pual VM, et al. 2019. PLOS Biology. 17(10):e3000492. PubMed Barnes SE, et al. 2021. J Neuroinflammation. 18:199. PubMed Sountoulidis A, et al. 2012. PLoS One. 7:e41460. PubMed Kwiecien K, et al. 2020. Sci Rep. 10:13702. PubMed Christin JR, et al. 2020. Cell Reports. 31(10):107742. PubMed Buffolo M, et al. 2019. Cell Rep. 29:270. PubMed Fu NY, et al. 2018. Dev Cell. 47:629. PubMed Chen Z, et al. 2020. Cell Death Dis. 11:180. PubMed Budai Z, et al. 2021. Cells. 10:. PubMed De Micheli AJ, et al. 2020. Cell Rep. 30:3583. PubMed Aoto M, et al. 2019. FEBS Open Bio. 9:291. PubMed E O’Koren, R Mathew, D Saban 2016. Sci Rep. 6:20636. PubMed Miao Y et al. 2019. Cell. 177(5):1172-1186 . PubMed Seong J, et al. 2018. Development. 145:14. PubMed Samuelson DR, et al. 2021. Commun Biol. 4:997. PubMed |
|---|
| RRID | AB_312968 (BioLegend Cat. No. 103103) AB_312969 (BioLegend Cat. No. 103104) |
|---|
| Structure | Protein tyrosine phosphatase (PTP) family, 180-240 kD |
|---|
| Distribution | All hematopoietic cells except mature erythrocytes and platelets |
|---|
| Function | Phosphatase, T and B cell activation |
|---|
| Ligand/Receptor | Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1 |
|---|
| Cell Type | B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs |
|---|
| Biology Area | Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells |
|---|
| Molecular Family | CD Molecules |
|---|
| Antigen References | 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85. 3. Kishihara K, et al. 1993. Cell 74:143. 4. Pulido R, et al. 1988. J. Immunol. 140:3851. |
|---|
| Gene ID | 19264 |
|---|
| UniProt | View information about CD45 on UniProt.org |
|---|
| Clone | 30-F11 |
|---|
| Regulatory Status | RUO |
|---|
| Other Names | T200, Ly-5, LCA |
|---|
| Isotype | Rat IgG2b, κ |
|---|
